Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:50:51 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CSTL - CASTLE BIOSCIENCES INC - https://ir.castlebiosciences.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CSTL - Q2.516.23·17.000.116.54-0.85-4.9463.77,3456,78817.705  17.7165  16.412535.84  15.4518:46:10Jul 1715 min RT 2¢

Recent Trades - Last 10 of 6788
Time ETExPriceChangeVolume
18:46:10Q16.80-0.5983
18:23:44Q16.25-1.146
16:33:10Q16.54-0.851,572
16:26:41Q16.79-0.604
16:20:00Q16.54-0.851
16:10:03Q16.54-0.851
16:10:03Q16.54-0.851
16:10:03Q16.54-0.851
16:10:03Q16.54-0.851
16:04:16Q16.54-0.851

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-17 07:00U:CSTLNews ReleaseCastle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture
2025-07-14 07:00U:CSTLNews ReleaseCastle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
2025-06-19 07:00U:CSTLNews ReleaseCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-16 16:30U:CSTLNews ReleaseCastle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
2025-06-11 07:00U:CSTLNews ReleaseCastle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
2025-06-04 07:00U:CSTLNews ReleaseCastle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards(TM)
2025-05-29 16:30U:CSTLNews ReleaseNew Data at ASCO 2025 Affirms DecisionDx(TM)-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
2025-05-21 07:00U:CSTLNews ReleaseCastle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
2025-05-09 07:00U:CSTLNews ReleaseReal-World Study Confirms Long-Term Performance of DecisionDx(TM)-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
2025-05-07 07:00U:CSTLNews ReleaseCastle Biosciences Celebrates Skin Cancer Awareness Month
2025-05-05 16:06U:CSTLNews ReleaseCastle Biosciences Reports First Quarter 2025 Results
2025-05-05 16:05U:CSTLNews ReleaseCastle Biosciences to Acquire Previse
2025-05-02 16:30U:CSTLNews ReleaseNew Data at DDW 2025 Further Demonstrates the TissueCypher(TM) Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
2025-04-30 17:00U:CSTLNews ReleaseNew Study Shows Castle Biosciences' DecisionDx(TM)-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
2025-04-28 07:00U:CSTLNews ReleaseDecisionDx(TM)-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
2025-04-25 16:15U:CSTLNews ReleaseNew Data at AACR Annual Meeting Highlights Use of DecisionDx(TM)-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
2025-04-14 07:00U:CSTLNews ReleaseCastle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
2025-04-08 07:00U:CSTLNews ReleaseCastle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
2025-04-07 07:00U:CSTLNews ReleaseCastle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
2025-04-03 07:00U:CSTLNews ReleasePublication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx(TM)-Melanoma Test